What did @alemacedos_vencedora actually say?
Honestly? Not much that we can verify. The transcript attached to this video is essentially incoherent, a garbled mix of unrelated sentences about houses, language learning, and bus trips that bears no relationship to the caption's claims about GHK-Cu peptide therapy. The caption, however, makes several specific promises: that this is her 26th dose of GHK-Cu, and that the peptide delivers collagen stimulation, improved skin elasticity, and firmer skin. Those are the claims worth examining, because 41,500 people watched this video.
The caption frames this as "informative content," which is a common workaround on Brazilian social media to imply educational value without triggering platform health claim restrictions. The hashtags point to flacidez (skin laxity) and colágeno (collagen), making the therapeutic intent clear even if the spoken content does not.
Does the science back this up?
There is legitimate preliminary research behind GHK-Cu, but it is nowhere near strong enough to justify the confidence implied by a 26-dose personal protocol posted to tens of thousands of followers. Most of the evidence is in vitro or animal-based, not human clinical trials.
The foundational work comes from Loren Pickart, who first isolated GHK-Cu in the 1970s and has published extensively on its biological activity. In vitro studies, including Pickart and Margolina (2018, Biomolecules), show GHK-Cu can upregulate genes associated with collagen synthesis and downregulate matrix metalloproteinases that break down skin structure. That is real, peer-reviewed data. A small human study by Leyden et al. (1994, Skin Pharmacology) found improved skin density and reduced fine lines with topical application, but the sample size was limited and the study design had weaknesses.
Subcutaneous or injectable GHK-Cu, which is the implied route given the "dose" framing here, has almost no robust human clinical trial data. Animal studies show wound healing and anti-inflammatory effects, but extrapolating that to human skin firmness after 26 doses is a stretch the current literature does not support.
What did they get wrong (or right)?
The caption claims are directionally plausible but overstated. GHK-Cu does appear to interact with collagen synthesis pathways in lab settings. Calling it a collagen stimulator is not fabricated. What is missing is the critical context: route of administration matters enormously, dosing in humans is not established, and the regulatory status of injectable GHK-Cu varies by country.
What they got wrong is the implied certainty. Framing this as a routine with 26 doses, presented to a large audience, suggests a level of established protocol that does not exist in the clinical literature. There are no phase III trials on injectable GHK-Cu for skin laxity in humans. Presenting personal use as informational content blurs the line between anecdote and evidence in a way that could mislead viewers into sourcing and self-administering unregulated peptides.
The transcript itself cannot be fact-checked because it is unintelligible relative to the topic. That is its own problem. If your spoken content and your caption are not aligned, the "informative content" label becomes harder to defend.
What should you actually know?
GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. Concentrations decline with age, which is one reason researchers have looked at it as a potential anti-aging compound. The biology is interesting. The leap from interesting biology to a personal dosing protocol promoted on social media is a large one.
If you are curious about peptide therapy for skin health, the honest answer is that topical formulations have more human data behind them than injectable versions. Topical GHK-Cu products are cosmetically available and carry a different risk profile than self-administered subcutaneous peptides, which require sterile preparation, proper storage, and medical oversight.
Anyone considering peptide therapy should consult a licensed physician or dermatologist, not a 41,000-view Instagram video. Compounded peptides sourced outside of regulated pharmacy channels carry contamination risks that no amount of anecdotal "dose 26" updates can offset. The science on GHK-Cu is worth watching. It is not yet worth replicating at home based on social content.
The bottom line
GHK-Cu has real biological plausibility for collagen-related effects, supported by in vitro and limited human topical studies. The injectable protocol implied here has no established clinical evidence base for the claims made. The transcript provides nothing checkable. The caption provides claims that are exaggerated relative to the actual state of the evidence. Viewers deserve that distinction made clearly.